In conclusion, we successfully constructed the CAR-NK cells using the HER2 affibody as the extracellular receptor and compared the anti-breast cancer effects of the affibody-directed CAR-NK with the traditional scFv-directed CAR-NK. Here, ERBB2 is linked to breast cancer.